Sign In
Buy OPGN
$24.75
+0 (+0%)
At Close: Jun 02, 2026
OpGen Stock Gains On FDA Approval, Interim Q3 Sales
08:46am, Monday, 04'th Oct 2021
The FDA has granted 510(k) clearance to OpGen Inc's (NASDAQ: OPGN) Acuitas AMR Gene Panel. The Company is finalizing preparations for its commercial launch in the U.S. in Q4 of 2021.
OpGen stock rockets after upbeat revenue update
07:46am, Monday, 04'th Oct 2021
Shares of OpGen Inc. OPGN, -4.17% rocketed 31.9% in active premarket trading Monday, after the precision medicine company provided a revenue update following the recent Food and Drug Administration cl
OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2021
07:30am, Monday, 04'th Oct 2021
ROCKVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat
OPGN Stock: Why It Noticeably Increased Today
06:10am, Monday, 04'th Oct 2021
The stock price of OpGen Inc (NASDAQ: OPGN) increased by over 15% pre-market today. This is why it happened.
OpGen Initiates Clinical Trial for Unyvero Urinary Tract Infection Panel
07:30am, Thursday, 30'th Sep 2021
ROCKVILLE, Md., Sept. 30, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat
Best Penny Stocks To Buy Now? Watch These 5 Today
08:21am, Wednesday, 22'nd Sep 2021
Are These On Your Penny Stocks Watch List Today? The post Best Penny Stocks To Buy Now?
- Unyvero reduced the use of inappropriate antibiotic therapy by 45.1%
4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507%
12:21pm, Tuesday, 14'th Sep 2021
Biotech Penny Stocks Surge As Sector Reverses Course The post 4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507% appeared first on Penny Stocks to Buy, Picks, News and Information
OpGen, Inc. (OPGN) CEO Oliver Schacht on Q2 2021 Results - Earnings Call Transcript
10:45pm, Thursday, 12'th Aug 2021
OpGen, Inc. (OPGN) CEO Oliver Schacht on Q2 2021 Results - Earnings Call Transcript
OpGen, Inc. (OPGN) Reports Q2 Loss, Misses Revenue Estimates
09:35pm, Thursday, 12'th Aug 2021
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 0.00% and -22.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update
04:15pm, Thursday, 12'th Aug 2021
Conference call to be held at 4:30 p.m. Eastern Daylight Savings Time today
OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:48pm, Wednesday, 04'th Aug 2021
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting
04:30pm, Wednesday, 04'th Aug 2021
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informati
OpGen to Provide Business Update and Financial Results for the Second Quarter 2021 on August 12th at 4:30 p.m. Eastern Time
07:30am, Wednesday, 04'th Aug 2021
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second qu
OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program
07:30am, Tuesday, 03'rd Aug 2021
- OpGen subsidiary Curetis and its instrument development partner have completed assembly of 10 final pre-series release A30 RQ analyzers
